法尼甾体X受体
化学
磺胺
药理学
对抗
敌手
脂质代谢
脂肪组织
代谢途径
胆汁酸
高脂血症
G蛋白偶联胆汁酸受体
胆固醇
生物化学
核受体
受体
结构-活动关系
脂蛋白
内科学
新陈代谢
内分泌学
作者
Lingyu Su,Tongyu Huo,Xinyi Zhao,Zichen Pang,Tzumei Wang,Yameng Liu,Xiaodong Dou,Ning Jiao
标识
DOI:10.1021/acs.jmedchem.5c03064
摘要
Farnesoid X receptor (FXR) plays a critical role in regulating bile acid and lipid metabolism, and intestinal FXR antagonism contributes to significant metabolic improvements. Herein, we report the discovery of a series of FXR antagonists featuring an N -ethyl sulfonamide scaffold. Through systematic structural optimization and structure–activity relationship studies, 101 derivatives were synthesized, among which F44-S101 was identified as a potent and selective intestine-restricted FXR antagonist with an IC 50 value of 0.48 μM. In Triton-induced hyperlipidemic mice, F44-S101 significantly reduced total cholesterol, triglycerides, and low-density lipoprotein cholesterol levels. In high-fat diet-fed mice, F44-S101 ameliorated lipid metabolic disorders, decreased adipose mass, and lowered serum ceramide levels. Mechanistically, F44-S101 selectively antagonizes intestinal FXR and feedback-activates hepatic FXR, thereby promoting cholesterol metabolism and reducing lipid accumulation. Collectively, these findings highlight F44-S101 as a promising lead compound for hyperlipidemia and support intestinal FXR antagonism as a potential therapeutic strategy for metabolic disorders.
科研通智能强力驱动
Strongly Powered by AbleSci AI